

sequence is inserted into a deleted E1 region of said non replicative recombinant adenoviral vector and is under the control of a promoter selected from the promoter contained in the Long Terminal Repeat of Rous Sarcoma Virus, the promoter of the IE gene of cytomegalovirus, the Mouse Mammary Tumor Virus inducible promoter and the metallothionein promoter wherein said polypeptide is expressed *in vivo* in muscle cells for at least 90 days after administration of said composition and is distributed throughout the muscle mass;

and (ii) a pharmaceutically acceptable carrier.